Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial

Lancet

Volumn 360, Issue 9344, 2002, Pages 1441-1447

  Eriksson, Bengt I ^a   Bergqvist, David ^b   Kälebo, Peter ^a   Dahl, Ola E ^c   Lindbratt, Siv ^d   Bylock, Anders ^e   Frison, Lars ^e   Eriksson, Ulf G ^e   Welin, Lennart ^e   Gustafsson, David ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Scandinavian Clinical Research Institute   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; MELAGATRAN; XIMELAGATRAN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHLEBOGRAPHY; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VEIN THROMBOSIS;

EID: 0037048939     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11469-3     Document Type: Article

References (22)

1. Hull R., Raskob G., Pineo G., et al. A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med. 329:1993;1370-1376.
2. Geerts W., Heit J., Clagett P., et al. Prevention of venous thrombosis. Chest. 119:2001;S132-S175.
3. Mohr D.N., Silverstein M.D., Murtaugh P.A., Harrison J.M. Prophylactic agents for venous thrombosis in elective hip surgery - meta-analysis of studies using venographic assessment. Arch Intern Med. 153:1993;2221-2228.
4. Eriksson U.G., Johansson L., Frison L., Bredberg U., Gustafsson D. Single and repeated oral dosing of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood. 94:(suppl):1999;26a.
5. Gustafsson D., Nystöm J-E., Carlsson S., et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 101:2001;171-181.
6. Eriksson U.G., Johansson L., Taure K., Frison L., Bredberg U., Gustafsson D. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor H 376/95 in healthy male subjects. Haemostasis. 30:(suppl):2000;164.
7. Johansson L.C., Eriksson U.G., Frison L., Fager G. Pharmacokinetics of H 376/95 in young and elderly healthy subjects. Blood. 96:2000;57a.
8. Eriksson B.I., Arfwidsson A-C., Frison L., et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of venous thromboembolism after total hip or total knee replacement: METHRO I. Thromb Haemost. 87:2002;231-237.
9. Rabinov K., Paulin S. Roentgen diagnosis of venous thromboembolism in the leg. Arch Surg. 104:1972;134-144.
10. Kälebo P., Ekman S., Lindbratt S., et al. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost. 76:1996;893-896.
11. Biello D.R., Mattar A.G., McKnight R.C., Siegel B.A. Ventilation-perfusion studies in suspected pulmonary embolism. AJR Am J Roentgenol. 133:1979;1033-1037.
12. Eriksson B.I., Wille-Jorgensen P., Kalebo P., et al. A comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 337:1997;1329-1335.
13. Eriksson B.I., Ekman S., Kälebo P., Zachrisson B., Bach D., Close P. Prevention of deep vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 347:1996;635-639.
14. Hull R.D., Pineo G.F., Francis C., et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 160:2000;2199-2207.
15. Dahl O.E., Aspelin T., Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coag Fibrinol. 6:1995;709-717.
16. Havig Ö. Deep vein thrombosis and pulmonary embolism: an autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand. 478:(suppl):1977;1-120.
17. Moser K.M., LeMoine J.R. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 94:1981;439-444.
18. Eriksson B.I., Kälebo P., Anthymyr B.A., Wadenvik H., Tengborn L., Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 73:1991;484-493.
19. Collins R., Scrimgeour A., Yusuf S., Peta R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopaedic, and urologic surgery. N Engl J Med. 318:1988;1162-1173.
20. Ginsberg J.S., Nurmohamed M.T., Gent M., et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation. 90:1994;2385-2389.
21. Francis C.W., Pellegrini V.D. Jr, Totterman S., et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am. 79:1997;1365-1372.
22. Lindbratt S., Eriksson B.I., Ekman S., Ahnfeld L., Close P. Less influence on liver enzymes with recombinant hirudin, CGP 39 393, (™Revasc-Ciba), compared to unfractionated heparin, in patients undergoing total hip replacement. Thromb Haemost. 73:(suppl):1995;1452.